Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) YoY EBITDA Growth : 48.61% (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Freeline Therapeutics Holdings's YoY EBITDA Growth for the quarter that ended in Sep. 2023 was 48.61%.

Freeline Therapeutics Holdings's EBITDA per Share for the three months ended in Sep. 2023 was $-2.67.

Freeline Therapeutics Holdings YoY EBITDA Growth Historical Data

The historical data trend for Freeline Therapeutics Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings YoY EBITDA Growth Chart

Freeline Therapeutics Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

YoY EBITDA Growth

-60.29

25.82

36.96

58.42

Freeline Therapeutics Holdings Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
YoY EBITDA Growth	Get a 7-Day Free Trial													63.82	68.33	61.16	35.17	48.61

Freeline Therapeutics Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Freeline Therapeutics Holdings's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

	YoY EBITDA Growth (A: Dec. 2022 )
=	(EBITDA per Share (A: Dec. 2022 )	-	EBITDA per Share (A: Dec. 2021 ))	/	\| EBITDA per Share (A: Dec. 2021 ) \|
=	(-23.677	-	-56.94)	/	\| -56.94 \|
=	58.42 %

Freeline Therapeutics Holdings's YoY EBITDA Growth for the quarter that ended in Sep. 2023 is calculated as:

	YoY EBITDA Growth (Q: Sep. 2023 )
=	(EBITDA per Share (Q: Sep. 2023 )	-	EBITDA per Share (Q: Sep. 2022 ))	/	\| EBITDA per Share (Q: Sep. 2022 )) \|
=	(-2.671	-	-5.198)	/	\| -5.198 \|
=	48.61 %

Freeline Therapeutics Holdings YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP

Website

https://www.freeline.life

Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.